-
公开(公告)号:US20190048043A1
公开(公告)日:2019-02-14
申请号:US16176200
申请日:2018-10-31
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
IPC分类号: C07K14/005
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号:US20220084624A1
公开(公告)日:2022-03-17
申请号:US17536896
申请日:2021-11-29
发明人: Lars Hangartner , Andrew B. Ward , Matteo Bianchi , Hannah Turner
IPC分类号: G16B15/00 , G16B25/20 , H01J37/26 , G01N33/564
摘要: Provided herein are methods for mapping immune response to an immunogen, comprising: immunizing a subject with an immunogen and obtaining sera from the immunized subject at multiple time intervals following immunization, wherein the sera comprises one or more immune complexes between the immunogen and serum antibodies; imaging, by electron microscopy, the sera obtained from the immunized subject in each of the time intervals, to obtain structural images of the one or more immune complexes formed between the immunogen and serum antibodies; mapping immune response to the immunogen by measuring differences in structural images obtained at different time intervals to simultaneously visualize diverse antibodies targeting distinct epitopes in the immunized subjects. Further provided herein are vaccine design processes, comprising: administering a proposed vaccine to a test subject; imaging the immune complex formed in the test subject upon administration of the proposed vaccine; processing and visualizing the image to determine the likely immunogenicity of the proposed vaccine, and determining that the proposed vaccine is immunogenic if it binds to an antibody, and determining that the proposed vaccine should be redesigned if it does not bind or binds weakly to the antibody.
-
公开(公告)号:US20240233873A9
公开(公告)日:2024-07-11
申请号:US18547705
申请日:2022-02-24
发明人: Andrew B. Ward , Aleksandar Antanasijevic , Charles Bowman , Christopher Cottrell , Gabriel Ozorowski , Robert Kirchdoerfer
IPC分类号: G16B30/10 , G01N33/577
CPC分类号: G16B30/10 , G01N33/577
摘要: Provided herein are methods for discovery of epitope specific monoclonal antibodies to pathogens directly from immune sera for immunotherapeutic use. Further provided herein are methods to determine molecular structure of antibodies targeting an antigen from convalescent or vaccinated individuals for the purpose of rational vaccine design.
-
公开(公告)号:US20240083954A1
公开(公告)日:2024-03-14
申请号:US18449739
申请日:2023-08-15
发明人: Leopold Kong , Ian A. Wilson , Natalia de Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
IPC分类号: C07K14/16 , A61K39/21 , A61K47/69 , C07K14/005
CPC分类号: C07K14/162 , A61K39/21 , A61K47/6929 , C07K14/005 , A61K39/12 , C12N2740/16122 , C12N2740/16134
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号:US20240136019A1
公开(公告)日:2024-04-25
申请号:US18547705
申请日:2022-02-24
发明人: Andrew B. Ward , Aleksandar Antanasijevic , Charles Bowman , Christopher Cottrell , Gabriel Ozorowski , Robert Kirchdoerfer
IPC分类号: G16B30/10 , G01N33/577
CPC分类号: G16B30/10 , G01N33/577
摘要: Provided herein are methods for discovery of epitope specific monoclonal antibodies to pathogens directly from immune sera for immunotherapeutic use. Further provided herein are methods to determine molecular structure of antibodies targeting an antigen from convalescent or vaccinated individuals for the purpose of rational vaccine design.
-
公开(公告)号:US11236134B2
公开(公告)日:2022-02-01
申请号:US16780495
申请日:2020-02-03
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号:US11767347B2
公开(公告)日:2023-09-26
申请号:US17553070
申请日:2021-12-16
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
CPC分类号: C07K14/162 , A61K39/21 , A61K47/6929 , C07K14/005 , A61K39/12 , A61K47/64 , A61K2039/5258 , A61K2039/6031 , A61K2039/645 , C12N2740/16122 , C12N2740/16134
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号:US20220098244A1
公开(公告)日:2022-03-31
申请号:US17553070
申请日:2021-12-16
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
IPC分类号: C07K14/16 , A61K47/69 , A61K39/21 , C07K14/005
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
公开(公告)号:US20200165303A1
公开(公告)日:2020-05-28
申请号:US16780495
申请日:2020-02-03
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
IPC分类号: C07K14/005 , A61K39/12 , A61K47/64 , A61K47/69
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
10.
公开(公告)号:US10647748B2
公开(公告)日:2020-05-12
申请号:US16176200
申请日:2018-10-31
发明人: Leopold Kong , Ian A. Wilson , Natalia De Val , Andrew B. Ward , Dennis Burton , Linling He , Jiang Zhu
IPC分类号: C07K14/005 , A61K39/12 , A61K47/64 , A61K47/69 , A61K39/00
摘要: The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
-
-
-
-
-
-
-
-
-